0721 TWO TIMES GREATER RISK FOR NEW ONSET MENTAL DISORDERS AMONG PATIENTS WITH PRIMARY RESTLESS LEGS SYNDROME RECEIVING DE NOVO DOPAMINE AGONISTS: A LARGE-SCALE RETROSPECTIVE CLAIMS MATCHED COHORT ANALYSIS

Abstract Introduction: FDA-approved treatments for primary Restless Legs Syndrome (PRLS), a sensorimotor neurological disorder, include a calcium channel ɑ2-δ ligand (gabapentin enacarbil) and dopamine agonists (DAs; pramipexole, ropinirole, and rotigotine). Increased risk for mental disorders among...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Sleep (New York, N.Y.) N.Y.), 2017-04, Vol.40 (suppl_1), p.A267-A267
Hauptverfasser:	Hankin, C, Lee, D, Wang, Z, Small, MB
Format:	Artikel
Sprache:	eng
Schlagworte:	Cohort analysis Dopamine Mental disorders Parkinson's disease Patients Restless legs syndrome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!